SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 03/15/24
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsGlobeNewsWire • 03/08/24
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) ConferenceGlobeNewsWire • 03/01/24
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and TimeGlobeNewsWire • 02/29/24
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in OncotargetGlobeNewsWire • 02/06/24
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) ConferenceGlobeNewsWire • 01/25/24
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia PatientsGlobeNewsWire • 01/09/24
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural MesotheliomaGlobeNewsWire • 12/27/23
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasGlobeNewsWire • 12/21/23
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid LeukemiaGlobeNewsWire • 12/14/23
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid LeukemiaGlobeNewsWire • 12/04/23
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid LeukemiaGlobeNewsWire • 11/29/23
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)GlobeNewsWire • 11/13/23
SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 202GlobeNewsWire • 11/06/23
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 10/31/23
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell LymphomasGlobeNewsWire • 10/30/23
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual GlGlobeNewsWire • 10/17/23
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid LeukemiaGlobeNewsWire • 10/16/23
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid LeukemiaGlobeNewsWire • 10/12/23
